Open access peer-reviewed Edited Volume

Mesothelioma - Diagnostics, Treatment and Basic Research

Ilze Strumfa

Riga Stradiņš University

Professor, MD, Ph.D. Ilze Strumfa received the Riga Stradins University (RSU) "Lecturer of the Year" Annual Award (2018) as the most distinguished teacher with over 10 years of teaching experience. As the Head of the Department of Pathology at RSU, she is also leading a skilled, motivated team of teachers and scientists that have won the awards of the Best academic unit (2011), Best Ph.D. student (2012), and Best digital junior teacher (2016).


Mesothelioma Asbestos BAP1 Pleural Mesothelioma Peritoneal Mesothelioma Pathogenesis Radiology Cytology Pleural Biopsy Surgical Treatment Chemotherapy Radiotherapy

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

The book aims to focus on the state of the art, pitfalls and perspectives in the diagnostics and treatment of mesothelioma – a peculiar malignant tumour, arising from mesothelial cells that line the pleura, the pericardium and the peritoneum. Mesothelioma is known for strong association with asbestos exposure, difficult surgical treatment and dismal prognosis. However, recent years have yielded significant discoveries, e.g., on germline mutations in BAP1 gene coding BRCA1-associated protein 1, pathogenetic role of inflammation, and innovative treatment approaches like immune checkpoint blockers and PARP inhibitors. The current book intends to summarise the classic concepts and innovations in the diagnostics, treatment and scientific studies of mesothelioma, resulting in a comprehensive reference for clinicians as well as a source of ideas for relevant clinical and basic research. We welcome high-quality original studies, meta-analyses and literature reviews. Case reports are encouraged as an attractive form of scientific article, preferably supplemented by a scientifically sound literature review ensuring a representative insight in the given pathology.

The topics broadly include but are not limited to:

1) Epidemiology and legal aspects of mesothelioma: global and regional incidence and mortality, epidemiological time trends and geographic variations, local experience, limitations and bias affecting diagnostics and coding of mesothelioma, asbestos-related legislation, historical use of asbestos.
2) Causes of mesothelioma: asbestos, asbestiform fibres, non-asbestos causes, germline mutations of BAP1, mismatch repair genes, TP53, BRCA2 and other genes, gene-environment interaction in mesothelioma.
3) Pathogenesis of mesothelioma: asbestos-induced cytotoxicity, role of local inflammation, including M2 macrophages and/or reactive oxygen species among other mechanisms, markers of systemic inflammation (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Glasgow Prognostic Score etc.), BAP1-related molecular pathways, other genetic and epigenetic alterations, miRNAs, stemness, tumour microenvironment and hypoxia.
4) Radiology in diagnostics and staging of mesothelioma: computed tomography, positron emission tomography and magnetic resonance imaging.
5) Tissue-based diagnostics of mesothelioma: cytology, histology and immunohistochemistry, informativity and limitations of the relevant methods, markers for differential diagnosis between benign versus malignant mesothelial cells and primary versus metastatic neoplasms in pleura or peritoneum, diagnostic protocols and algorithms, future developments via digital pathology, machine-based learning etc.
6) Clinical and histological features of BAP1-associated mesothelioma.
7) Liquid biopsy in mesothelioma: proteins, miRNAs, CTC, ctDNA etc.
8) Staging and prognosis of mesothelioma: state of the art, techniques and limitations of current staging systems, survival and prognostic factors, long-term survival.
9) Surgical management of mesothelioma: benefits and controversies of extrapleural pneumonectomy, pleurectomy/decortication (P/D) and extended P/D.
10) Systemic chemotherapy, immune checkpoint inhibitors, BAP1-pathway-targeting agents, PARP inhibitors and other innovations, mechanisms of chemoresistance in mesothelioma.
11) Radiotherapy.
12) Intracavitary chemo- and/or photodynamic therapy.
13) Peritoneal mesothelioma (PM): cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy.
14) Rare locations and histological types: pericardiac mesothelioma, multicystic mesothelioma etc.
15) Mesothelioma in wild and domestic animals.
16) Communication and support: communicating diagnosis to the patient, palliative treatment, nutritional maintenance and psychological support.

Publishing process

Book initiated and editor appointed

Date completed: September 3rd 2021

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: October 1st 2021

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: November 30th 2021

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: February 18th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: April 19th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Ilze Strumfa

Riga Stradiņš University

Professor, MD, Ph.D. Ilze Strumfa is an outstanding medical lecturer, actively involved in the research in pathology. She graduated from the Medical Academy of Latvia with distinction (1998), underwent board certification in pathology (2001), and received a Ph.D. degree in 2005. Currently, she holds the positions of professor and head of the Department of Pathology in the Riga Stradins University (RSU), Latvia. Her 10 years of teaching experience have culminated with the RSU "Lecturer of the Year" Annual Award (2018), given to the most distinguished teachers. As the Head of the Department of Pathology, she is leading a skilled, motivated team of teachers and scientists that have won the awards for the Best academic unit (2011), Best Ph.D. student (2012), and Best digital junior teacher (2016). Prof. Strumfa is an author/co-author of more than 90 peer-reviewed journal articles and 16 chapters in scientific monographs and medical textbooks. She has been acting as the leading expert in several European and national research projects devoted to the development of diagnostic technologies, neuroendocrine and endocrine tumors, breast cancer, laboratory training in research, and tumor microenvironment. Her main research interests include morphological and molecular diagnostics and prognostic assessment of tumors, as well as digital pathology and other innovations in pathology and cytology.

View profile

Book chapters authored 12

Books edited 1

Introducing your Author Service Manager

Mrs. Mia Vulovic

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in